Address: Rue de Stallestraat 63/4, B-1180 Brussels,Belgium
Tel:
Web: http://www.octapharma.com/en.html
Our Group-wide mission is the safe and optimal use of human proteins.
Octapharma respects donated human plasma as a scarce and valuable resource. We meet our Mission through the use of cutting-edge, validated viral inactivation and state-of-the-art purification technologies, in order to achieve the highest production yields and manufacture medical products with the highest possible safety margins. We respect human plasma as a sparce resource for life saving therapies.
The Octapharma portfolio focuses on protein and other biopharmaceutical products derived from human plasma, in three therapeutic areas:
Haematology
Coagulation factors to treat bleeding disorders.
Intensive Care and Emergency Medicine
Plasma and blood proteins (such as albumin) used to stabilise blood circulation, restore coagulation function, and prevent shock, e.g., for heavy burns, injuries, and in surgery.
Immunotherapy
Immunoglobulins to treat immune disorders and prevent rhesus incompatibility in pregnancies.
Historically, Belgium is widely recognized as a major regional hub for clinical development. How would you compare the current environment to 1999, when Archemin was first established, and how has…
An in-depth viewpoint on the current taxation situation for pharmaceutical companies operating in Belgium today, looking at incentive programs and relative positioning in Europe. Mr Eynatten, can you please…
Deloitte is certainly renowned for its strong network of international expertise in the field of life sciences having teams in all of the crucial markets able to cater to their…
Deloitte is certainly renowned for its strong network of international expertise in the field of life sciences having teams in all of the crucial markets able to cater to their…
Donald Niesten and Omer Saka discuss the current dynamics of the healthcare and pharmaceutical sectors in Belgium, the challenges of entering the market and the issue of effective communication…
Mr Pasini, before becoming site director of the Verviers plant you were acting as the Head of Investor Relations for Lonza. Can you provide us with an overview of your…
This August marks your sixth year at the helm of the Belgian affiliate of Ferring, what would you say best explains your loyalty to the company? One element that appeals…
UCB was founded in 1928 by Mr Emmanuel Janssen in Belgium, what spirit would you say its founder left behind and what core values unique to the company were you…
Since 1969, Eli Lilly & Company has been investing in Belgium. Can you give our readers a brief overview of the company’s history here and highlight some of your most…
The managing director of Brussels Invest & Export discusses Belgium’s unique attractiveness when it comes to the life sciences, and which countries and companies are interested in investing in the…
Could you tell our readers who are not familiar with the Biopark with an introduction of the Biopark and its institutes? The BioPark of Charleroi Brussels South is a campus…
The generics market in Belgium doesn’t seem to be at the level it deserves to be. Considering that Mylan controls about 14% of the local generics market share, how would…
See our Cookie Privacy Policy Here
